IL308099A - Orexin receptor agonists and uses thereof - Google Patents

Orexin receptor agonists and uses thereof

Info

Publication number
IL308099A
IL308099A IL308099A IL30809923A IL308099A IL 308099 A IL308099 A IL 308099A IL 308099 A IL308099 A IL 308099A IL 30809923 A IL30809923 A IL 30809923A IL 308099 A IL308099 A IL 308099A
Authority
IL
Israel
Prior art keywords
receptor agonists
orexin receptor
orexin
agonists
receptor
Prior art date
Application number
IL308099A
Other languages
English (en)
Hebrew (he)
Inventor
Prafulkumar Chovatia
Claudia Beato
Gilles Ouvry
Davide Marinelli
Original Assignee
Jazz Pharmaceuticals Ireland Ltd
Prafulkumar Chovatia
Claudia Beato
Gilles Ouvry
Davide Marinelli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jazz Pharmaceuticals Ireland Ltd, Prafulkumar Chovatia, Claudia Beato, Gilles Ouvry, Davide Marinelli filed Critical Jazz Pharmaceuticals Ireland Ltd
Publication of IL308099A publication Critical patent/IL308099A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D515/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL308099A 2021-05-03 2022-05-03 Orexin receptor agonists and uses thereof IL308099A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163183321P 2021-05-03 2021-05-03
PCT/EP2022/061851 WO2022233872A1 (en) 2021-05-03 2022-05-03 Orexin receptor agonists and uses thereof

Publications (1)

Publication Number Publication Date
IL308099A true IL308099A (en) 2023-12-01

Family

ID=81940742

Family Applications (1)

Application Number Title Priority Date Filing Date
IL308099A IL308099A (en) 2021-05-03 2022-05-03 Orexin receptor agonists and uses thereof

Country Status (12)

Country Link
US (1) US20240254143A1 (enExample)
EP (1) EP4334323A1 (enExample)
JP (1) JP2024516033A (enExample)
KR (1) KR20240004802A (enExample)
CN (1) CN117616030B (enExample)
AU (1) AU2022269811A1 (enExample)
BR (1) BR112023022050A2 (enExample)
CA (1) CA3217403A1 (enExample)
IL (1) IL308099A (enExample)
MX (1) MX2023012971A (enExample)
TW (1) TW202309051A (enExample)
WO (1) WO2022233872A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260083444A (ko) 2019-11-25 2026-06-05 알케르메스,인코포레이티드 치환된 마크로사이클릭 화합물 및 관련 치료 방법
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
US12006330B2 (en) 2020-12-21 2024-06-11 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
JP7833486B2 (ja) 2021-05-26 2026-03-19 アルカーメス，インコーポレイテッド 置換されるカルバメート大環状化合物および関連のある治療方法
US20240425519A1 (en) * 2021-11-04 2024-12-26 University Of Washington Novel spirocyclic compounds as klhdc2 ligands
JP2026506356A (ja) 2023-01-31 2026-02-24 ジャズ ファーマシューティカルズ アイルランド リミテッド 大環状オレキシン受容体アゴニスト及びその使用
CN116478076A (zh) * 2023-04-26 2023-07-25 南京优氟医药科技有限公司 一种(2s,4s)-1-叔丁氧羰基-2-(二氟甲基)-4-羟基吡咯烷的制备方法
CN122374291A (zh) 2023-12-12 2026-07-10 爱杜西亚药品有限公司 作为食欲素受体调节剂的芳基砜及砜酮衍生物
WO2025132542A1 (en) 2023-12-19 2025-06-26 Idorsia Pharmaceuticals Ltd Macrocyclic orexin agonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0687268B1 (en) * 1993-03-04 1998-05-27 Pfizer Inc. Spiroazacyclic derivatives as substance p antagonists
EP0997464B1 (en) * 1998-10-23 2005-02-16 Pfizer Inc. 1,3,8-Triazaspiro[4,5] decanone compounds as orl1-receptor agonists
US8530648B2 (en) * 2009-12-21 2013-09-10 Novartis Ag Diaza-spiro[5.5]undecanes
US20120101110A1 (en) * 2010-10-26 2012-04-26 Sangamesh Badiger Diaza-spiro[5.5]undecanes
SG11201806429PA (en) * 2016-02-04 2018-08-30 Takeda Pharmaceuticals Co Substituted piperidine compound and use thereof
US11655241B2 (en) * 2018-06-29 2023-05-23 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US11098029B2 (en) * 2019-02-13 2021-08-24 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists

Also Published As

Publication number Publication date
WO2022233872A1 (en) 2022-11-10
EP4334323A1 (en) 2024-03-13
CA3217403A1 (en) 2022-11-10
TW202309051A (zh) 2023-03-01
CN117616030B (zh) 2026-06-19
CN117616030A (zh) 2024-02-27
KR20240004802A (ko) 2024-01-11
JP2024516033A (ja) 2024-04-11
MX2023012971A (es) 2024-01-16
AU2022269811A1 (en) 2023-11-16
US20240254143A1 (en) 2024-08-01
BR112023022050A2 (pt) 2023-12-26

Similar Documents

Publication Publication Date Title
ZA202212223B (en) Lpa receptor antagonists and uses thereof
IL309108A (en) Orexin sulfonamide receptor agonists and uses thereof
IL279224A (en) 1-GLP agonist receptors and their use
IL269068A (en) Paranoid X receptor agonists and uses thereof
SG11202011465QA (en) Glp-1 receptor agonists and uses thereof
IL281471A (en) Farnesoid x receptor agonists and uses thereof
SMT202600045T1 (it) Agonisti del recettore farnesoide x e loro usi
EP4247801A4 (en) 3-AMINO PYRROLIDINE AND MACROCYCLIC PIPERIDINE OREXIN RECEPTOR AGONISTS
IL326957A (en) Mrgprx2 antagonists and their uses
IL281474A (en) Farnesoid x receptor agonists and uses thereof
IL279152A (en) Melanocortin subtype-2 receptor antagonists and uses thereof
SG11202102651SA (en) Farnesoid x receptor agonists and uses thereof
IL277144A (en) Adenosine receptor antagonists and uses thereof
GB202002010D0 (en) Microtopographies and uses thereof
SMT202600046T1 (it) Agonisti di recettori di amilina con azione a lunga durata e loro usi
SG11202003274YA (en) Group iii base stocks and lubricant compositions
SG11202003726WA (en) Group iii base stocks and lubricant compositions
IL313687A (en) OXER1 antagonists and their uses
HK40107459A (en) Orexin receptor agonists and uses thereof
IL308183A (en) Multispecific FGF21 receptor agonists and their uses
HK40110668A (en) Sulfonamide orexin receptor agonists and uses thereof
HK40118469A (en) Lpa receptor antagonists and uses thereof
HK40109907A (en) Lpa receptor antagonists and uses thereof
HK40090520A (en) Lpa receptor antagonists and uses thereof
GB202404750D0 (en) Orexin receptor agonists